We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Industry Asks FDA to Focus Definition of Controlled Correspondence
Generics Industry Asks FDA to Focus Definition of Controlled Correspondence
Generic drugmakers want the FDA to better define what qualifies for a “controlled correspondence” under a draft guidance that aims to speed agency responses to manufacturer queries.